United States was the largest of BIO-TECHNE Corp’s 6 reported lines in fiscal 2026, at $635.37M — 52% of $1.22B.
| Geography | FY 2009 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $642.47M | $657.75M | $683.23M | $635.37M | |||||||||||||
| Emea, Excluding United Kingdom | $220.23M | $241.43M | $266.31M | $294.22M | |||||||||||||
| Emea, Excluding U.K | — | — | — | — | |||||||||||||
| Europe | — | — | — | — | |||||||||||||
| Apac, Excluding Greater China | $73.19M | $73.90M | $77.26M | $85.82M | |||||||||||||
| Greater China | $113.87M | $99.47M | $100.46M | $104.06M | |||||||||||||
| China | — | — | — | — | |||||||||||||
| United Kingdom | $49.46M | $50.01M | $54.83M | $56.28M | |||||||||||||
| Europe Other Than U.K | — | — | — | — | |||||||||||||
| Other Areas | — | — | — | — | |||||||||||||
| Other Asia | — | — | — | — | |||||||||||||
| Rest Of World | $37.49M | $36.50M | $37.55M | $39.29M | |||||||||||||
| Total | $1.14B | $1.16B | $1.22B | $1.22B |
In fiscal 2026, which ended June 30, 2026, the 6 regions BIO-TECHNE Corp reported in this breakdown added up to $1.22B. That was down 0.4% from $1.22B in fiscal 2025. United States was the largest region, at $635.37M or 52.3% of the total, followed by Emea, Excluding United Kingdom ($294.22M, 24.2%) and Greater China ($104.06M, 8.6%). Together, the two largest regions made up 76.5% of this total.
Compared with fiscal 2025, Apac, Excluding Greater China grew the fastest, rising 11.1% to $85.82M. United States fell the most, down 7.0% to $635.37M. Over fiscal 2023 to 2026, revenue across these regions went from $1.14B to $1.22B, a compound annual growth rate of 2.2%. United States' share of the total fell from 56.5% to 52.3% over the same years.
The table also keeps 6 regions that BIO-TECHNE Corp no longer reports, so earlier years can still be read on their original basis; use "Show 6 discontinued" beneath the table to see them. This breakdown covers 17 fiscal years between 2009 and 2026, as reported in BIO-TECHNE Corp's annual filings.
Protein Sciences was the largest of BIO-TECHNE Corp’s 2 reported lines in fiscal 2026, at $874.62M — 72% of $1.21B.
| Segment | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Protein Sciences | $845.75M | $830.90M | $870.25M | $874.62M | |||||||||||||||
| Diagnostics & Spatial Biology | $292.60M | $326.39M | $346.26M | $336.37M | |||||||||||||||
| Biotechnology | — | — | — | — | |||||||||||||||
| Diagnostics & Genomics | — | — | — | — | |||||||||||||||
| United States | — | — | — | — | |||||||||||||||
| Diagnostics | — | — | — | — | |||||||||||||||
| Europe | — | — | — | — | |||||||||||||||
| Protein Platforms | — | — | — | — | |||||||||||||||
| Clinical Controls | — | — | — | — | |||||||||||||||
| Other Asia | — | — | — | — | |||||||||||||||
| Hematology | — | — | — | — | |||||||||||||||
| Rest Of World | — | — | — | — | |||||||||||||||
| China | — | — | — | — | |||||||||||||||
| Other Revenue | — | $4.15M | $4.15M | — | |||||||||||||||
| Total | $1.14B | $1.16B | $1.22B | $1.21B |
In fiscal 2026, which ended June 30, 2026, the 2 segments BIO-TECHNE Corp reported in this breakdown added up to $1.21B. The segments reported changed from fiscal 2025, so the total is not directly comparable with the $1.22B reported that year. Protein Sciences was the largest segment, at $874.62M or 72.2% of the total, followed by Diagnostics & Spatial Biology ($336.37M, 27.8%).
Compared with fiscal 2025, Protein Sciences grew the fastest, rising 0.5% to $874.62M. Diagnostics & Spatial Biology fell the most, down 2.9% to $336.37M. Because segments were added or dropped between the two years, part of this reflects how BIO-TECHNE Corp regrouped its reporting. Over fiscal 2023 to 2026, revenue across these segments went from $1.14B to $1.21B, a compound annual growth rate of 2.1%. Protein Sciences' share of the total fell from 74.3% to 72.2% over the same years.
The table also keeps 12 segments that BIO-TECHNE Corp no longer reports, so earlier years can still be read on their original basis; use "Show 12 discontinued" beneath the table to see them. This breakdown covers 19 fiscal years between 2009 and 2026, as reported in BIO-TECHNE Corp's annual filings.
Consumables was the largest of BIO-TECHNE Corp’s 4 reported lines in fiscal 2026, at $680.85M — 75% of $910.77M.
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Consumables | $665.30M | $657.68M | $684.17M | $680.85M | ||||||
| Instruments | $112.09M | $108.27M | $112.09M | $110.63M | ||||||
| Services | $85.78M | $99.27M | $111.57M | $94.30M | ||||||
| Service | — | — | — | — | ||||||
| Royalty | $21.10M | $23.35M | $23.69M | $24.99M | ||||||
| Total | $884.27M | $888.56M | $931.51M | $910.77M |
In fiscal 2026, which ended June 30, 2026, the 4 revenue lines BIO-TECHNE Corp reported in this breakdown added up to $910.77M. That is less than the $1.22B in its breakdown by region, so these revenue lines do not account for all of its revenue that year. Consumables was the largest revenue line, at $680.85M or 74.8% of the total, followed by Instruments ($110.63M, 12.1%) and Services ($94.30M, 10.4%). Together, the two largest revenue lines made up 86.9% of this total.
Compared with fiscal 2025, Royalty grew the fastest, rising 5.5% to $24.99M. Services fell the most, down 15.5% to $94.30M.
The table also keeps 1 revenue line that BIO-TECHNE Corp no longer reports, so earlier years can still be read on their original basis; use "Show 1 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2017 to 2026, as reported in BIO-TECHNE Corp's annual filings.
BIO-TECHNE Corp (TECH) breaks its revenue down by region, segment and revenue line. In fiscal 2026, its largest region was United States, with $635.37M or 52.3% of the total, followed by Emea, Excluding United Kingdom at $294.22M (24.2%).
United States was BIO-TECHNE Corp's largest region in fiscal 2026, with $635.37M in revenue, 52.3% of the $1.22B reported across its 6 regions.
Protein Sciences was BIO-TECHNE Corp's largest segment in fiscal 2026, with $874.62M in revenue, 72.2% of the $1.21B reported across its 2 segments.
Consumables was BIO-TECHNE Corp's largest revenue line in fiscal 2026, with $680.85M in revenue, 74.8% of the $910.77M reported across its 4 revenue lines.
Of the BIO-TECHNE Corp regions reported in both fiscal 2025 and fiscal 2026, and making up at least 2% of the total, Apac, Excluding Greater China grew the fastest, rising 11.1% from $77.26M to $85.82M.
Every figure is taken from BIO-TECHNE Corp's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by region covers fiscal 2009 to 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.